Back to today’s briefing

Story perspectives

Syngene and Bristol Myers Squibb Extend Collaboration to 2035

1/19/2026

36 6 Full Breakdown

Summary

Story summary

Syngene International extended its strategic research collaboration with Bristol Myers Squibb to 2035.
The expanded agreement adds discovery, translational sciences, and clinical trials across development.
The collaboration began in 1998.
It led to the Biocon Bristol Myers Squibb Research and Development Center in 2009.
Payal Sheth, Bristol Myers Squibb Senior Vice President, emphasizes advancing science and patient outcomes.

1 of 1

Story summary

Syngene International extended its strategic research collaboration with Bristol Myers Squibb to 2035.
The expanded agreement adds discovery, translational sciences, and clinical trials across development.
The collaboration began in 1998.
It led to the Biocon Bristol Myers Squibb Research and Development Center in 2009.
Payal Sheth, Bristol Myers Squibb Senior Vice President, emphasizes advancing science and patient outcomes.